Commentary: Are There Indeed Spliced Peptides in the Immunopeptidome?

Area of Science:

• Immunology
• Proteasome Biology
• Mass Spectrometry

Background:

• Proteasome-generated spliced epitopes presented by HLA class I are key targets for T cell immunotherapies.
• Recent debates question the proteasome's ability to catalyze peptide splicing, suggesting identified peptides are artifacts.
• This challenges established findings since the discovery of proteasome-catalyzed peptide splicing in 2004.

Purpose of the Study:

• To address the ongoing debate surrounding the biological relevance of proteasome-generated spliced epitopes.
• To reconcile conflicting evidence regarding the in vivo generation of spliced peptides by the proteasome.
• To reaffirm the significance of spliced epitopes in T cell-mediated immunity and immunotherapy.

Main Methods:

• Review and synthesis of existing literature on proteasome function and peptide splicing.
• Analysis of mass spectrometry data from immunopeptidome studies.
• Comparison of in vitro, in cellula, and in vivo experimental results.

Main Results:

• Multiple studies provide evidence for proteasome-catalyzed peptide splicing occurring in vitro, in cellula, and in vivo.
• These findings contradict the hypothesis that all identified spliced peptides are artifacts.
• The biological significance of these spliced epitopes in T cell recognition is supported by experimental data.

Conclusions:

• Proteasome-catalyzed peptide splicing is a biologically relevant process.
• Spliced epitopes presented by HLA class I molecules are valid targets for T cell immunotherapies.
• Further research should focus on harnessing these epitopes for therapeutic strategies.